Covid, a young international team: that’s how Pomezia works on the vaccine
In an 80,000 m2 site 20 miles from Rome, young researchers from around the world work day and night making history. They have played a key role in the development of the Covid-19 vaccine, after the Jenner Institute (expert in…
IRBM to collaborate with MSD to develop peptides against coronavirus
Rome, Italy – IRBM, a global Contract Research Organization today announced a new research collaboration agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, NJ, USA) to identify and develop novel peptide therapeutics active against different strains of coronavirus, including SARS-CoV-2.
IRBM’s Advent announces manufacture of 13,000 doses of Covid-19 vaccine, for use in Phase 2/3 clinical trials by the University of Oxford
In Memory of Maurizio Botta: His Vision of Medicinal Chemistry
IRBM supporting the effort to cope with the impact of coronavirus
There are many ways to face the impact of coronavirus. Due to the worldwide pandemic, there is a blood shortage in several hospitals. The staff at IRBM set up, in partnership with Ema-Roma, a Blood Donation Day. This highly worthwhile…
IRBM’s Chief Science Officer, Carlo Toniatti is featured in the Medicine Maker’s Power List
Carlo joins other leading authorities in drug discovery and development as part of the Biopharmaceuticals category in the Medicine Maker Power List. In his interview he reviews future trends in drug development and some of the defining moments of his…
BBC came to film IRBM’s Advent GMP facility
Dihydroxypyrimidine Scaffold to Target HIV‑1 Nucleocapsid Protein
IRBM and their collaborators’ at the universities of Strasbourg and Siena have recently published a paper in the ACS Medicinal Chemistry Letters which describes their approach to the identification of a 5-dihydroxypyrimidine-6-carboxamide substructure as a privileged scaffold of a new…
The Medicine Maker. Onward in Oncology: Lessons Learned with Carlo Toniatti
IRBM’s Chief Science Officer, Carlo Toniatti is once again featured in the Medicine Maker. This time he takes us on a journey from the clinic, to academia, to industry – where he spent over two decades developing anti-cancer drugs. Carlo…